Resting Heart Rate (Pulse) Mega Study
Contents
Resting Heart Rate (Pulse)
Resting Heart Rate (Pulse)

Tags

Resting Heart Rate
Pulse
Resting Heart Rate (Pulse)

Abstract

This mega-study analyzes Resting Heart Rate (Pulse) (Vital Signs) using aggregated N-of-1 observational data from 148 participants who contributed 3,677 measurements . We identified 2,576 statistically significant predictor-outcome relationships involving Resting Heart Rate (Pulse).

Resting Heart Rate (Pulse) acts as both a predictor (affecting 418 outcomes) and an outcome (influenced by 2,158 factors). Effect sizes are reported as percent change from baseline, enabling direct comparison across measures.

Our analysis employs within-subject comparisons to control for individual differences, temporal precedence analysis to assess causality direction, and the Predictor Impact Score (PIS) to quantify causal evidence. See the ranked results below to explore the full list of factors predicting Resting Heart Rate (Pulse).

Keywords: Resting Heart Rate (Pulse), Vital Signs, N-of-1 trials, real-world evidence, causal inference, Predictor Impact Score, observational study

Full Methodology: Framework for Real-World Evidence-Based Pharmacovigilance: Aggregated N-of-1 Trials for Quantifying Treatment Effects

High Confidence: With 148 participants, these findings have strong statistical power. Results are significant at p < 0.05.

Results

Our analysis identified 2,576 statistically significant relationships involving Resting Heart Rate (Pulse). This includes 418 outcomes affected by Resting Heart Rate (Pulse) and 2,158 predictors of Resting Heart Rate (Pulse).

Click any relationship in the tables below to view the full study page with detailed charts, statistical analysis, temporal parameters, and methodology for that specific predictor-outcome pair.

Relationship Network

The network graph below visualizes the relationships between Resting Heart Rate (Pulse) and related variables. Nodes represent variables, and edges represent statistically significant relationships. Click any node or edge to explore that relationship.

Causal Flow Diagram

The Sankey diagram below illustrates the flow of influence between predictors, Resting Heart Rate (Pulse), and outcomes. The width of each flow corresponds to the strength of the relationship. Click any flow to see the detailed study.

Predictors of Resting Heart Rate (Pulse)

The table below ranks predictors by their impact on Resting Heart Rate (Pulse). Each row shows the percent change in Resting Heart Rate (Pulse) following above-average predictor exposure. Click any row to see the full analysis.

PUZZLED_ROBOT
Don't see what you're looking for?

Less than 1% of patients are able to participate in clinical trials! :(

Take 30 seconds to make it possible for all patients to easily participate in trials for the most promising treatments!

Predictors
of
Below is the change in after each predictor is higher than average.
Sort by % Change
Sort by Evidence
Sort by Participants
Predictor
% Change from Baseline
*
Change from average after above-average predictor exposure.
Note: Results are based on aggregated observational data. Confidence increases with more participants. Click any row for full study details.

Summary Statistics

Resting Heart Rate (Pulse) Info

Property Value
Variable Name Resting Heart Rate (Pulse)
Aggregation Method MEAN
Analysis Performed At 2022-08-15
Duration of Action 24 hours
Kurtosis 3.342903614242
Maximum Allowed Value 300 beats per minute
Mean 70.824646616541 beats per minute
Median 70.568541353383 beats per minute
Minimum Allowed Value 20 beats per minute
Number of Aggregate Predictors 2158
Number of Aggregate Outcomes 418
Number of Measurements 3677
Number of Measurements (including those generated by tagged, joined, or child variables) 3677
Public true
Onset Delay 0 seconds
Standard Deviation 3.3013064237832
Unit Beats per Minute
User Variables 148
UPC 714169039954
Variable Category Vital Signs
Variable ID 5211891
Variance 15.937331897943

Introduction

Background

Resting Heart Rate (Pulse) (Vital Signs) acts as both a modifiable factor (predictor) and a measurable health outcome. Understanding the predictors and outcomes associated with Resting Heart Rate (Pulse) has important implications for personalized health optimization, clinical decision-making, and public health interventions. Traditional randomized controlled trials (RCTs), while the gold standard for causal inference, are often impractical for studying the full range of factors that may influence vital signs.

Research Questions

This mega-study addresses the following research questions:

  1. What factors most strongly predict changes in Resting Heart Rate (Pulse)?
  2. What health outcomes are most affected by changes in Resting Heart Rate (Pulse)?
  3. What is the magnitude of these effects (percent change from baseline)?
  4. How confident can we be in these relationships?

Study Overview

We employ an aggregated N-of-1 observational study design, combining data from multiple individual longitudinal natural experiments. This approach leverages within-subject comparisons to control for stable individual differences while aggregating across participants to identify population-level patterns.

Discussion

Interpretation of Findings

The ranked tables in the Results section provide a comprehensive list of predictors, ordered by their effect size on Resting Heart Rate (Pulse). Rather than focusing on any single relationship, the value lies in the full spectrum of factors identified and their relative effect sizes.

Context and Prior Research

These findings should be interpreted in the context of existing literature on Resting Heart Rate (Pulse). While our observational design cannot establish causality with the certainty of randomized trials, the large sample size, within-subject design, and temporal precedence analysis provide converging evidence for the relationships identified.

Practical Implications

Individuals seeking to optimize their Resting Heart Rate (Pulse) may consider the predictors identified in this analysis, particularly those that are directly modifiable (e.g., behaviors, treatments, environmental factors). However, individual responses may vary, and these population-level findings should not replace personalized medical advice.

Future Directions

Future research should examine:

  • Subgroup analyses to identify individual differences in response
  • Potential confounders and mediators of the observed relationships
  • Optimal dosing and timing for modifiable predictors
  • Confirmation of key findings through prospective or randomized designs

Conclusion

The ranked tables above provide the complete list of factors predicting Resting Heart Rate (Pulse), ordered by effect size.

These findings may inform evidence-based strategies for optimizing Resting Heart Rate (Pulse). Individual responses may vary; consult healthcare providers for personalized guidance.

Help End Unnecessary Suffering

Current clinical trials are 82x more expensive than necessary and take 17 years to bring treatments to market. Pragmatic trials integrated into standard healthcare could reduce costs from $41,000 to $500 per participant and compress timelines to just 2 years. Learn how redirecting just 1% of global military spending could accelerate cures for the 2 billion people suffering from treatable diseases.

Methods

Study Design

Our analysis of Resting Heart Rate (Pulse) is based on aggregated data from 148 separate N-of-1 observational natural experiments. Unlike traditional clinical trials, our approach captures relationships in everyday life conditions, providing insights into how factors actually affect people outside controlled laboratory settings. Each participant serves as their own control, reducing between-subject confounding.

Baseline & Outcome Measurement

For each participant \(i\), we compute the mean predictor value and partition measurements into baseline (below-average exposure) and follow-up (above-average exposure) periods:

$$\text{Baseline}_i = \{(p, o) : p < \bar{p}_i\} \quad \text{Follow-up}_i = \{(p, o) : p \geq \bar{p}_i\}$$

The primary effect size is expressed as percent change from baseline:

$$\Delta\% = \frac{\mu_{\text{follow-up}} - \mu_{\text{baseline}}}{\mu_{\text{baseline}}} \times 100$$

This metric is interpretable ("15% reduction in symptoms"), scale-invariant, and consistent with FDA efficacy assessments.

Temporal Analysis & Causality Direction

Our analysis accounts for two critical temporal parameters:

  • Onset Delay (\(\delta\)): Time lag between predictor exposure and observable outcome change (0-100 days)
  • Duration of Action (\(\tau\)): Time window over which predictor influence persists (10 min - 90 days)

We compute both forward correlations (predictor → outcome) and reverse correlations (outcome → predictor) to calculate the temporality factor:

$$\phi_{\text{temporal}} = \frac{|r_{\text{forward}}|}{|r_{\text{forward}}| + |r_{\text{reverse}}|}$$

A temporality factor approaching 1.0 indicates the predictor reliably precedes the outcome, supporting a causal interpretation. Values near 0.5 suggest ambiguous temporal direction, while values approaching 0 suggest reverse causation.

Temporal Parameter Optimization

Different predictor-outcome pairs have different optimal temporal alignments. We employ hyperparameter optimization to find the onset delay and duration that maximize correlation strength:

$$(\delta^*, \tau^*) = \underset{\delta, \tau}{\text{argmax}} \; |r(\delta, \tau)|$$

The search begins with category-appropriate defaults (e.g., 30-minute onset for treatments) and explores physiologically plausible ranges. To prevent overfitting, we restrict searches to biologically plausible ranges and require minimum sample sizes.

Statistical Methods

We employ multiple statistical techniques:

  • Pearson Correlation Coefficient:
    $$r = \frac{\sum_{j=1}^{n}(p_j - \bar{p})(o_j - \bar{o})}{\sqrt{\sum_{j=1}^{n}(p_j - \bar{p})^2} \cdot \sqrt{\sum_{j=1}^{n}(o_j - \bar{o})^2}}$$
  • Z-Score Normalization: Effect magnitude relative to baseline variability:
    $$z = \frac{|\Delta\%|}{\text{RSD}_{\text{baseline}}}$$
    where \(z > 2\) indicates \(p < 0.05\) (statistically significant)
  • Two-Tailed T-Tests: Statistical significance assessed at \(\alpha = 0.05\)
  • 95% Confidence Intervals: \(\text{CI}_{95\%} = \bar{r} \pm 1.96 \cdot \text{SE}_{\bar{r}}\)

Effect Size Classification

Correlation strength is classified based on the absolute coefficient value:

Classification Correlation Range
Very Strong\(|r| \geq 0.8\)
Strong\(0.6 \leq |r| < 0.8\)
Moderate\(0.4 \leq |r| < 0.6\)
Weak\(0.2 \leq |r| < 0.4\)
Very Weak\(|r| < 0.2\)

Data Quality Requirements

To ensure reliable results, we enforce minimum thresholds:

  • ≥ 5 distinct value changes in both predictor and outcome variables
  • ≥ 30 overlapping measurement pairs (per Central Limit Theorem)
  • ≥ 10% of data in both baseline and follow-up periods
  • Non-zero variance in both predictor and outcome

Our filling strategy is deliberately conservative: zero-filling for treatments assumes non-adherence when no measurement exists, biasing toward null findings rather than false positives.

Predictor Impact Score (PIS)

We calculate a composite Predictor Impact Score that quantifies how much a predictor impacts an outcome:

$$\text{PIS} = |r| \cdot S \cdot \phi_z \cdot \phi_{\text{temporal}} \cdot f_{\text{interest}}$$

Where:

  • \(|r|\) = absolute correlation coefficient (strength)
  • \(S = 1 - p\) = statistical significance
  • \(\phi_z = \frac{|z|}{|z| + 2}\) = normalized z-score factor (effect magnitude)
  • \(\phi_{\text{temporal}}\) = temporality factor (forward vs. reverse causation)
  • \(f_{\text{interest}}\) = interest factor (penalizes spurious variable pairs)

Higher PIS values indicate predictors with greater, more reliable impact on the outcome.

Bradford Hill Criteria for Causality

While correlation does not prove causation, our PIS operationalizes six of the nine Bradford Hill criteria:

Criterion How Addressed Metric
StrengthEffect size magnitude\(|r|\), \(\Delta\%\)
ConsistencyCross-participant replication\(N\), \(n\), SE, CI
TemporalityForward vs. reverse correlation\(\phi_{\text{temporal}}\)
Biological GradientDose-response analysis\(\phi_{\text{gradient}}\)
SpecificityCategory appropriateness\(f_{\text{interest}}\)
PlausibilityCommunity votingUp/down votes

Confidence Levels

Each relationship is assigned a confidence level based on multiple factors:

  • High Confidence: \(p < 0.01\), or \(N > 100\) participants, or \(n > 500\) pairs
  • Medium Confidence: \(p < 0.05\), or \(N > 10\) participants, or \(n > 100\) pairs
  • Low Confidence: Meets minimum thresholds but requires more data

Limitations

Key limitations of this observational framework:

  • Cannot prove causation: Unmeasured confounders may influence results
  • Self-selection bias: Health trackers may differ from general population
  • Measurement error: Self-reported data may contain recall bias
  • Confounding by indication: Sicker patients may take more treatments

These findings represent population-level trends and should not replace personalized medical advice. Within-subject comparison and temporal precedence analysis partially mitigate these limitations.

Population Analysis

With 148 participants contributing data, our analysis benefits from the Law of Large Numbers: as sample size increases, random noise diminishes and true relationships become more apparent. Population-level estimates are computed as:

$$\bar{r} = \frac{1}{N} \sum_{i=1}^{N} r_i \quad \text{with} \quad \text{SE}_{\bar{r}} = \frac{\sigma_r}{\sqrt{N}}$$

Principal Investigator

Program & Methods

Mike P. Sinn

Designed and implemented data collection, aggregation, causal inference pipeline, and automated study generation framework. Developed the Predictor Impact Score methodology operationalizing Bradford Hill criteria for ranking causal relationships in observational data. When he tells people this at parties, they usually say they have to go check on their car.

Individual study outputs are automated, reproducible, and open to external audit. (Which I would seriously recommend.)

Cite This Study

APA Format
Sinn, M. P. (2026). Resting Heart Rate (Pulse) Mega-Study: Systematic Analysis of Causes and Effects [Data set; N=148]. The Decentralized FDA. http://studies.dfda.earth/variables/Resting_Heart_Rate_(Pulse)
BibTeX
@misc{sinn_5211891_2026,
  author = {Sinn, Mike P.},
  title = {Resting Heart Rate (Pulse) Mega-Study: Systematic Analysis of Causes and Effects},
  year = {2026},
  publisher = {The Decentralized FDA},
  url = {http://studies.dfda.earth/variables/Resting_Heart_Rate_(Pulse)},
  note = {Accessed: January 7, 2026},
  howpublished = {N=148 participants}
}
Chicago/Turabian
Sinn, Mike P. "Resting Heart Rate (Pulse) Mega-Study: Systematic Analysis of Causes and Effects." Data set, N=148. The Decentralized FDA. Accessed January 7, 2026. http://studies.dfda.earth/variables/Resting_Heart_Rate_(Pulse).
Harvard
Sinn, M.P., 2026. Resting Heart Rate (Pulse) Mega-Study: Systematic Analysis of Causes and Effects. [Aggregated N-of-1 Study, N=148] The Decentralized FDA. Available at: http://studies.dfda.earth/variables/Resting_Heart_Rate_(Pulse) [Accessed January 7, 2026].

Study Type: Aggregated N-of-1 Observational Mega-Study
Evidence Level: Level II (Real-World Evidence)
Methodology: Bradford Hill Criteria with Predictor Impact Score (PIS)

References

This framework was originally developed in 2013 based on the Bradford Hill criteria. Subsequent literature has independently validated similar approaches to causal inference from observational data:

  1. Hill, A.B. (1965). The environment and disease: association or causation? Proceedings of the Royal Society of Medicine, 58(5), 295-300. [Bradford Hill criteria]
  2. Lillie, E.O., et al. (2011). The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine, 8(2), 161-173. [N-of-1 methodology]
  3. Pearl, J. (2009). Causality: Models, Reasoning, and Inference . Cambridge University Press. [Causal inference]
  4. Hernán, M.A., & Robins, J.M. (2020). Causal Inference: What If . Chapman & Hall/CRC. [Free textbook]
  5. FDA (2018). Framework for FDA's Real-World Evidence Program . U.S. Food and Drug Administration. [Regulatory context]
  6. Duan, N., et al. (2013). Single-patient (n-of-1) trials: a pragmatic clinical decision methodology . Journal of Clinical Epidemiology, 66(8), S21-S28.
  7. Platt, R., et al. (2018). The FDA Sentinel Initiative—an evolving national resource . New England Journal of Medicine, 379(22), 2091-2093.

This information is for research and educational purposes only, not medical advice. Consult a healthcare provider before making health decisions. Terms of Service